Japanese Research Finds Tamiflu And Relenza Early Administration Reduces Fever Symptoms
This article was originally published in PharmAsia News
Executive SummaryA research study released by Japan's National Institute of Infectious Disease found that patients affected with new strains of H1N1 flu virus who received earlier administration of flu drugs such as Tamiflu (oseltamivir) or Relenza(zanamivir) had shorter periods of fever symptoms. Conducted in Osaka with 171 patients, the research found that on average patients treated within 24 hours of infection had fever systems that lasted 1.9 days; those treated after one day had a fever for 2.5 days and those who were treated between two to five days had a fever for 3-4 days. (Click here for more - Japanese language
You may also be interested in...
UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.
As part of its response to the coronavirus outbreak, Medicines for Europe has set out a series of policy recommendations that it says could help to mitigate the risks of COVID-19.
The coronavirus COVID-19 outbreak poses a “limited immediate risk” to European production and supplies of off-patent drugs, according to industry association Medicines for Europe. However, if the situation continues for an extended period an “important impact” cannot be ruled out.